Generics group established first voice for biosimilars in Canada

Generics and biosimilars Initiative

Building trust in cost-effective treatments

Inscribirse
eng / esp

Generics group established first voice for biosimilars in Canada

Biosimilares/General | Posted 27/04/2015 0 Post your comment

The Canadian Generic Pharmaceutical Association (CGPA), which represents Canada’s generics industry, announced on 7 April 2015 that it had set up a new CGPA Biosimilars Board, with Mr Michel Robidoux, President and General Manager of Sandoz Canada, as its inaugural Chair.

Canada’s federal department responsible for health, Health Canada, finalized guidelines for biosimilars, or subsequent entry biologics (SEBs), as they are called in Canada, in March 2010 [1]. To date, Health Canada has approved three SEBs within the product classes of human growth hormone and TNF-inhibitor, for use in Canada [2].

The establishment of the new CGPA Biosimilars Board signifies the focus the Canadian generics industry is placing on ensuring that Canada is a viable market for biosimilars, according to Mr Robidoux. ‘The establishment of clear rules for the approval and reimbursement of cost-saving biosimilar products in Canada is essential for the ongoing sustainability of both public and employer-sponsored drug plans, and to ensure that more Canadians can gain access to the treatments they need,’ he added.

In Canada, four of the five top-selling prescription drugs are biologicals with annual sales of more than CA$2 billion.

The CGPA Biosimilars Board aims to play an important role in educating patients, prescribers and drug plan sponsors about biosimilars in Canada.

Editor’s comment
Subsequent entry biologics approved in Canada have been authorized following a strict regulatory process in the same way as is required for approval of biosimilars in the European Union. The EMA (European Medicines Agency) regulatory requirements ensure the same high standards of quality, safety and efficacy for biosimilars as for originator biologicals and also include a rigorous comparability exercise with the reference product.

Canada-EU trade deal will extend patents for two years

References
1. GaBI Online - Generics and Biosimilars Initiative. Canadian guidelines for subsequent entry biologics [www.gabionline.net]. Mol, Belgium: Pro Pharma Communications International; [cited 2015 Apr 27]. Available from: http://www.gabionline.net/Guidelines/Canadian-guidelines-for-subsequent-entry-biologics
2. GaBI Online - Generics and Biosimilars Initiative. Subsequent entry biologics approved in Canada [www.gabionline.net]. Mol, Belgium: Pro Pharma Communications International; [cited 2015 Apr 27]. Available from: www.gabionline.net/Biosimilars/General/Subsequent-entry-biologics-approved-in-Canada

Permission granted to reproduce for personal and non-commercial use only. All other reproduction, copy or reprinting of all or part of any ‘Content’ found on this website is strictly prohibited without the prior consent of the publisher. Contact the publisher to obtain permission before redistributing.

Source: CGPA